Evidence map›Paper›PMID 42041226›Full record

ArticleBriefings in bioinformatics2026

ZeCardioAI: combining zebrafish, AI, and xAI for an in-depth cardiac phenotyping platform.

Ferran Arqué, Carole Jung, Beatriz Muriel-Moreno, Laura López-Blanch, Eduardo Saman, Davide D'Amico, Javier Terriente, Paula Petrone, Sylvia Dyballa

Erratum issuedAbstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ferran ArquéEarly Drug Discovery Department, ZeCardio Therapeutics, Carrer de Laureà Miró, 408, 410, 08980 Barcelona, Spain.ORCID 0009-0008-4037-3457
Carole JungTechnology and Innovation Department, ZeClinics SL, Carrer de Laureà Miró, 408, 410, 08980 Barcelona, Spain.ORCID 0000-0002-0239-0343
Beatriz Muriel-MorenoTechnology and Innovation Department, ZeClinics SL, Carrer de Laureà Miró, 408, 410, 08980 Barcelona, Spain.ORCID 0000-0002-6683-9082
Laura López-BlanchTechnology and Innovation Department, ZeClinics SL, Carrer de Laureà Miró, 408, 410, 08980 Barcelona, Spain.ORCID 0000-0001-8905-7094
Eduardo SamanTechnology and Innovation Department, ZeClinics SL, Carrer de Laureà Miró, 408, 410, 08980 Barcelona, Spain.ORCID 0000-0002-2825-8172
Davide D'AmicoTechnology and Innovation Department, ZeClinics SL, Carrer de Laureà Miró, 408, 410, 08980 Barcelona, Spain.ORCID 0000-0002-9000-7403
Javier TerrienteTechnology and Innovation Department, ZeClinics SL, Carrer de Laureà Miró, 408, 410, 08980 Barcelona, Spain.ORCID 0000-0002-0426-9862
Paula PetroneBiomedical Data Science Group, Institut de Salut Global de Barcelona (ISGlobal), Carrer del Doctor Aiguader, 88, 08003 Barcelona, Spain.ORCID 0000-0002-5030-1915
Sylvia DyballaTechnology and Innovation Department, ZeClinics SL, Carrer de Laureà Miró, 408, 410, 08980 Barcelona, Spain.ORCID 0000-0002-2485-0638

Funding

Agencia Estatal de InvestigaciónAyudas para Doctorados Industriales DIN 2022-012817 to F.A.Ministerio de Ciencia e InnovaciónNextGenEU programme "Artificial Intelligence and Other Digital Technologies to Drive Their Integration into Value Chains" NextGenEU-C005/21-ED 2021/C005/00149851
6 · The paper itself

Abstract

Artificial intelligence (AI) integrated with high-throughput assays offers a powerful route to accelerate discovery in relevant biological models. Functional cardiac imaging is a prime application, where deep learning (DL) and explainable AI (xAI) can overcome limitations of traditional phenotyping methods, such as manual analysis, subjective interpretation, and low scalability. In cardiovascular research, the zebrafish model is highly valuable due to its translational relevance and accessibility for high-throughput applications. Here, we present ZeCardioAI, a computational platform combining zebrafish experimental advantages with DL and xAI methodologies. The platform automatically extracts comprehensive cardiac phenotypes from live imaging, achieving high precision while maintaining interpretability, critical for mechanistic insight and translational validation. ZeCardioAI, when applied to zebrafish models of dilated and hypertrophic cardiomyopathy (CM), detected subtle yet clinically relevant phenotypic differences. Machine learning classifiers achieved robust separation of disease from healthy phenotypes, and xAI revealed discriminative features aligning with established clinical markers. Our developments should prove valuable in addressing the unmet medical need in CMs to find new, specific treatments. The platform's modular architecture supports future adaptation to diverse disease contexts beyond CMs, enabling large-scale, fully automated phenotyping at a throughput unattainable by manual approaches. ZeCardioAI establishes a new standard for AI-powered biological research, offering transformative potential for accelerating drug discovery, advancing precision medicine approaches, and deepening fundamental understanding of complex biological systems across multiple therapeutic areas.

Indexed as

Artificial IntelligenceCardiomyopathy, HypertrophicDeep LearningHeartZebrafishAnimalsDisease Models, AnimalHumansMachine LearningPhenotypeartificial intelligencecardiomyopathyexplainable AImachine learningphenotypingzebrafish

Identifiers

PMID42041226
PMCPMC13112437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.